The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus
Authors:
- Claudio Galarza-MaldonadoCGClaudio Galarza-Maldonado
- María R. KourilovitchMKMaría R. Kourilovitch
- Ricard CerveraRCRicard Cervera
- 1 December 2010
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 10 (2) , 108-111
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- B Cell-Targeted Therapies for Systemic Lupus ErythematosusDrugs, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patientsArthritis Care & Research, 2009
- Requirement of B Cells for Generating CD4+ T Cell MemoryThe Journal of Immunology, 2009
- Altered B cell receptor signaling in human systemic lupus erythematosusAutoimmunity Reviews, 2009
- Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in miceProceedings of the National Academy of Sciences, 2007
- EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases, 2007
- Immunotherapy of systemic lupus erythematosusAutoimmunity Reviews, 2005
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002